Try our Advanced Search for more refined results
- Law360
- Law360 UK
- Law360 Pulse
- Law360 Employment Authority
- Law360 Tax Authority
- Law360 Insurance Authority
- Law360 Real Estate Authority
- Law360 Healthcare Authority
- Law360 Bankruptcy Authority
- Products
- Lexis®
- Law360 In-Depth
- Law360 Podcasts
- Rankings
- Regional Powerhouses
- Law360's MVPs
- Women in Law Report
- Law360 400
- Diversity Snapshot
- Practice Groups of the Year
- Rising Stars
- Titans of the Plaintiffs Bar
- Sections
- Adv. Search & Platform Tools
- About all sections
- Browse all sections
- Banking
- Bankruptcy
- Class Action
- Competition
- Employment
- Energy
- Expert Analysis
- Insurance
- Intellectual Property
- Product Liability
- Securities
- Beta Tools
- Track docs
- Track attorneys
- Track judges
In re Forest Laboratories, Inc. Securities Litigation
Case Number:
1:05-cv-02827
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
- Brodsky Smith
- Cuneo Gilbert
- Debevoise & Plimpton
- Keker Van Nest & Peters
- Milberg Coleman
- Motley Rice
- Robbins Geller
Companies
Sectors & Industries:
-
February 02, 2009
Coughlin Stoia Attys Seek $18M In Celexa Deal Fees
Lead counsel for the plaintiffs in a securities class action alleging that Forest Laboratories Inc. provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro have asked for more than $18 million in fees and expenses.
-
December 29, 2008
Forest's $65M Settlement Over Antidepressants OK'd
A judge has given preliminary approval to a $65 million settlement that allows Forest Laboratories to end a securities class action that claimed it provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro.
-
November 11, 2008
Forest Labs To Settle Shareholders' Suit For $65M
Forest Laboratories Inc. has reached a tentative settlement of $65 million in a securities class action that claimed the company provided misleading information about the safety of its blockbuster antidepressants, Celexa and Lexapro.
-
October 29, 2007
Judge Certifies Forest Labs Shareholder Class
A judge in the multidistrict securities litigation against Forest Laboratories Inc. on Friday granted class status to a group of plaintiffs that say the drug maker provided misleading information about the safety of its blockbuster antidepressants Celexa and Lexapro.